onoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications

including cancer, cardiovascular disease, autoimmune disorders and infectious disease. An important mechanism of action (MoA) of monoclonal antibodies used in cancer treatment is the antibody-dependent cell- mediated cytotoxicity (ADCC). Selecting suitable cell lines and optimising culture conditions towards expression of antibody candidates with desired ADCC activity is an essential part of the R&D process. A fast and straightforward approach to easily access ADCC activity facilitates screening of a large number of clones or monitoring the effect of upstream process variations. ADCC starts with the binding of the antibody to a cancer cell. Binding of the Fc domain of that antibody to Fcy receptors of effector cells triggers a process that finally kills the cancer cell. Te interaction of the FcyIIIa receptor with the Fc domain is strongly influenced by the N-glycans of the antibody. As the Fcy receptor IIIa plays an key role in the ADCC process antibodies with high affinity for Fcy receptor IIIA are considered to have a high ADCC activity.

FC RECEPTOR AFFINITY TSKgel FcR-IIIA-NPR is a new HPLC affinity column developed by Tosoh Corporation that is based on a recombinant version of the FcyIIIa receptor. It could be demonstrated that FcyRIIIa affinity chromatography allows fast evaluation of biologic activity and glycoform pattern of antibodies.[1]

Terminal galactose residues

increase affinity to FcyRIIIa while core fucose residues reduce it. Tis correlates with the known influence of galactose and fucose on ADCC activity. Accordingly, early eluting peaks of TSKgel FcR-IIIA-NPR represent glycoforms with low ADCC activity while late eluting peaks represent glycoforms with high ADCC activity (Fig.1).

SEPARATION OF MAB GLYCOFORMS Fig.2 A and B demonstrate the ability of the recombinant FcyRIIIA ligand to separate antibody glycoforms depending on the structure of the oligosaccharides bound to the Fc domain of mAbs. Trastuzumab analysed with TSKgel FcR- IIIA-NPR (Fig.2A) shows a typical pattern of three peaks, corresponding with the molecule’s glycan heterogeneity. Based on the relatively high amount of fucose units the chromatogram shows a high amount


Fig.1. Analysis of mAb glycoforms according to their affinity to Fc Receptor/ADCC activity

Regina Römling explains how HPLC is assessing antibody- dependent cell-mediated cytotoxicity

of glycoforms with lower Fc receptor affinity. Te corresponding analysis of a glycoengineered non-fucosylated Trastuzumab (Fig. 2B)reveals the presence of large amounts of glycoforms with high Fc receptor affinity. Tese non-fucosylated mAb glycoforms are supposed to show enhanced ADCC. Te enhanced ADCC activity of the non- fucosylated antibody could be confirmed by ADCC reporter bioassay (data not shown).

HPLC Conditions: Column:

TSKgel FcR-IIIA-NPR (5 µm, 4.6 mm ID x 7.5 cm L)

Mobile Phase: A: 50 mmol/L sodium citrate, pH 6.5;

B: 50 mmol/L sodium citrate, pH 4.5

Flow Rate: 1 mL/min Temp.:


Detection: UV @ 280nm Sample:

Trastuzumab; non- fucosylated Trastuzumab

A rapid 30-minute separation on TSKgel FcR-IIIA-NPR allows the analysis of large numbers of mAb samples to gain valuable first information on the distribution of glycoforms and expected ADCC activity. Tis fast and efficient method can be applied to purified samples and supernatant alike and can therefore be used in many phases of development and production, such as cell line screening in early R&D, biosimilar/

Fig.2. Analysis of Trastuzumab (A) and non-fucosylated Trastuzumab (B) (Data kindly provided by Leila Ghaleh, TU Darmstadt)

REFERENCES [1]. M. Kiyoshi et al., Sci. Rep. 8: 3955 (2018) doi:10:1038/ s41598-018-22199-8

Regina Römling is with Tosoh Bioscience.


originator comparison, upstream development and optimisation, monitoring of glycoengineering, or lot-to-lot comparison in QC.

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72